The "Motoric Cognitive Risk" Syndrome in the Canadian Population

NCT ID: NCT03679026

Last Updated: 2024-04-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1461 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-22

Study Completion Date

2024-12-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cognition and locomotion are two human abilities controlled by the brain. Their decline is highly prevalent with aging, and is greater than the simple sum of their respective prevalence, suggesting a complex age-related interplay between cognition and locomotion. Recently, a systematic review and meta-analysis has provided evidence that poor gait performance predicts dementia and, in particular, has demonstrated that "motoric cognitive risk" (MCR) syndrome, which has been described in cognitively healthy individuals and combines subjective cognitive complaint with objective slow gait speed, is a pre-dementia syndrome. The uniqueness of "motoric cognitive risk" (MCR)syndrome is that it does not rely on a complex evaluation or laboratory investigations. Thus, it is easy to apply in population-based settings. The overall objective of the proposal is to examine the epidemiology of the newly reported "motoric cognitive risk" (MCR) syndrome, in the Quebec population using the database of the NuAge study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognition Disorders in Old Age Cardiovascular Diseases Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CVRF

individuals with cardio-vascular risk factors and diseases

Summarize of participants' characteristics using means and standard deviations or frequencies and percentages

Intervention Type OTHER

Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.

WCVRF

individuals without cardio-vascular risk factors and diseases

Summarize of participants' characteristics using means and standard deviations or frequencies and percentages

Intervention Type OTHER

Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Summarize of participants' characteristics using means and standard deviations or frequencies and percentages

Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals eligible for this study will be participants of the NuAge study

Exclusion Criteria

* Individuals not eligible for the NuAge study
* dementia
* mobility disability
* no information about cognitive complaint
* no measure of walking speed
Minimum Eligible Age

45 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jewish General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Olivier Beauchet

Professor of Geriatrics

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jewish General Hospital

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CODIM-FLP-16 261

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cohort Study on Cognitive Decline in Elderly
NCT07093892 NOT_YET_RECRUITING